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Summary (181 words; maximum 200 words) 
Patients with inherited factor VII (FVII) deficiency display different clinical phenotypes 
requiring ad hoc management. This study evaluated treatments for spontaneous and traumatic 
bleeding using data from the Seven Treatment Evaluation Registry (STER). One-hundred and one 
bleeds were analysed in 75 patients (41 females; FVII coagulant activity <1–20%). Bleeds were 
grouped as haemarthroses (n=30), muscle/subcutaneous haematomas (n=16), epistaxis (n=12), gum 
bleeding (n=13), menorrhagia (n=16), central nervous system (CNS; n=9), gastrointestinal (GI; 
n=2) and other (n=3). Of 93 evaluable episodes, 76 were treated with recombinant, activated FVII 
(rFVIIa), eight with fresh frozen plasma (FFP), seven with plasma-derived FVII (pdFVII) and two 
with prothrombin-complex concentrates. One-day replacement therapy resulted in very favourable 
outcomes in haemarthroses, and was successful in muscle/subcutaneous haematomas, epistaxis and 
gum bleeding. For menorrhagia, single- or multiple-dose schedules led to favourable outcomes. No 
thrombosis occurred; two inhibitors were detected in two repeatedly treated patients (one post-
rFVIIa, one post-pdFVII). In FVII deficiency, most bleeds were successfully treated with single 
‘intermediate’ doses (median 60 µg/kg) of rFVIIa. For the most severe bleeds (CNS, GI), short- or 
long-term prophylaxis may be optimal. 
 
Keywords: Bleeds, replacement therapy, factor VII deficiency 
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Introduction 
Inherited factor VII (FVII) deficiency is the most common of the rare autosomal recessive 
bleeding disorders, with an estimated prevalence of one per 300,000–500,000 in European 
countries; clinical features have been clearly defined in a number of recent publications (1-4). It is 
likely that the prevalence is higher in those countries where consanguineous marriages are frequent, 
especially with respect to the severe forms of the disease (5). 
Affected patients display a wide range of clinical phenotypes, from an asymptomatic 
condition to serious haemorrhagic episodes, such as fatal central nervous system (CNS), 
gastrointestinal (GI) or “spontaneous” joint and muscle bleeds (6, 7). Symptomatic patients can be 
divided into two major categories: those with a mild to moderate bleeding tendency and individuals 
with a very clear bleeding tendency that may be more severe than in haemophilia. The former group 
experience mainly mucosal bleeding, a clinical picture that mimics that of a platelet disorder and 
often does not necessitate treatment. In contrast, for the most severely affected patients suffering 
from life- or limb-threatening haemorrhages, aggressive Replacement Therapy (RT) and/or long-
term prophylaxis is required. Patients with clinically severe FVII deficiency commonly become 
symptomatic at a young age (e.g. soon after birth or in the first few years) and have low to very low 
levels of residual FVII, which are associated with severe causative F7 gene lesions (2, 7). 
In congenital bleeding disorders (CBD), the mainstay for bleeding management is RT based 
on the substitution of the missing factor, with the aim of correcting the clotting defect. For the 
management of FVII deficiency, a number of RTs (3), from plasma or plasma-derived to 
recombinant products, can be used. However, limited information is available regarding optimal 
treatment schedules and dosing as well as indications, treatment limitations and adverse events (8, 
9). We have therefore prospectively collected data from the Seven Treatment Evaluation Registry 
(STER) on large numbers of treatments for spontaneous or traumatic bleeding episodes and 
evaluated therapy schedules and adverse events. 
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Materials and Methods  
The STER is a prospective, observational, multicentre, Web-based registry created to collect 
and describe data on treatment modalities and outcomes in patients with congenital FVII deficiency. 
As treatment decisions, especially in rare CBD, are mostly based on personal clinical experience 
rather than on consolidated clinical evidence, the general purpose of the STER is to document 
treatment practices for “spontaneous” bleeds, surgery, prophylaxis and related adverse events. Since 
only a limited number of patients are available for follow-up in most treatment centres, the STER 
aims to elucidate treatment modalities in a well-defined population of FVII-deficient patients, 
carefully characterized according to their clinical and clotting phenotypes. The study protocol was 
created following strictly controlled data collection procedures set up by the International FVII 
Deficiency Study Group (IF7SG) based on the experience gained from previous studies (6, 7, 10, 
11). Data collected online are stored in a custom designed database. The STER system is a Web 
application and data are stored in a Microsoft SQL Server 2000 database, which contains the 
electronic case report form pages with no components installed on the centre computers. 
Investigators access the system when a patient needs a treatment for: (i) spontaneous bleeding 
episodes; (ii) prophylaxis courses; and (iii) surgical interventions. For spontaneous (or traumatic) 
bleeding episodes, the study protocol was designed to capture the following items: (i) type of 
bleeding; (ii) treatment site (home vs. hospital); (iii) relation to trauma; (iv) detail regarding 
substitution therapy; (v) concomitant medications (i.e. anti-fibrinolytics); (vi) concomitant illness; 
and (vii) adverse events (e.g. anaphylactoid reactions, inhibitor occurrence, thrombotic events, 
disseminated intravascular coagulation, bleeding and mortality). 
In order to evaluate only those subjects with a clear risk of bleeding (10, 11), only patients 
with FVII coagulant activity (FVIIc) levels ≤20% were considered (Table 1). Enrolment occurred 
only if the treating physician considered RT necessary to treat a bleeding episode. FVIIc was 
assayed at each participating centre using high-sensitivity thromboplastins in every instance 
(ISI~1). Patients were also carefully characterized with respect to their bleeding phenotype by 
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recording the number and type of different symptoms reported (Table 1). The following RT 
parameters were evaluated: (i) RT duration (days); (ii) total number of RT injections; (iii) total RT 
dose; (iv) mean daily dose (total dose/number of treatment days); and (v) mean single dose (total 
dose/number of injections) (Tables 2 and 3). Treating physicians performed bleeding diagnosis and 
management. Thrombosis diagnosis (venous or arterial) was based on clinical suspicion and 
confirmed by imaging. Screening for inhibitory antibodies to FVII was carried out in a central 
laboratory using a standard assay (Aarhus University Hospital, Skejby, Denmark and, after January 
2010, Guy’s & St. Thomas’ Hospital, London, UK) of baseline and 30-day plasma samples. The 
method used is a modification of the Bethesda assay, sensitive to 0.45 Bethesda units (BU)/ml of 
inhibitor, where 1 BU is the antibody amount capable of reducing FVII by 50% after two hours of 
incubation (12). The reference used to detect inhibitors to FVII was a pool of “normal” plasma. The 
inhibitor assay was not performed if baseline FVIIc levels were >4%.  
New records were reviewed by an adjudication committee (GM, AD) and an expert from the 
Central Records Office (see Acknowledgements), and investigators were asked to complete the file 
blanks prior to definitive approval. In order to provide information useful to the treating physicians, 
bleeding episodes were grouped into the following categories: (i) haemarthroses; (ii) muscle and 
subcutaneous haematomas; (iii) menorrhagia; (iv)  epistaxis; (v) gum bleeding; (vi) CNS and GI; 
(vii) other. 
Efficacy evaluation was performed six hours after RT, according to the following criteria:  
- Excellent: Single administration leading to cessation of overt bleeding and of related 
symptoms; prompt (within a few hours) relief of pain; disappearance of swelling and 
return to the previous range of joint or limb mobility. Cessation of bleeding was also 
evaluated by imaging if appropriate. 
- Effective: More than one administration was needed to obtain the same results as above.  
- Partially effective: More than one administration was needed, but symptoms subsided 
slowly and the return of limb and joint mobility was partial.  
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- Ineffective: There were no changes. 
- Not evaluable: No elements for evaluation were available.  
 The number of doses was considered the most important element in the outcome evaluation. 
For menorrhagia, treatment evaluation was performed after the end of the cycle. The research 
proposed by the STER Study Group was approved by the Ethics Committee of L’Aquila University 
(coordinator's institution) and, in parallel, by the committees of the other institutions involved. The 
STER protocol is publicly available at http://www.targetseven.org and published on 
http://clinicaltrials.gov (# NCT01269138). 
 
Statistical analysis  
Statistical descriptive measures, including the mean or median and range (variability), were 
calculated for each parameter evaluated, and performed using the MedCalc

 software version 
7.4.1.2 (Mariakerke, Belgium; http://www.medcalc.be). 
 
Results 
As of January 2012, management for 101 bleeds performed in 23 haemophilia treatment 
centres from 15 countries was observed in 75 patients with FVII deficiency (41 females and 34 
males, age range 0·1–71 years), with residual FVIIc levels ranging between <1 and 20% (Tables 1, 
2 and 3). All patients were previously symptomatic, with a wide array of symptom combinations 
(Tab. 1). Fifty-two patients (51%) were treated once, 19 patients twice, seven patients three and 
four times and, finally, 16 patients were treated five times or more. Detailed clinical and clotting 
phenotypes are shown in Table 1 (patients’ reference numbers given in Table 1 are reported in 
Tables 2 and 3). There was a higher percentage of females than males (54.7% vs. 45.3%) (Table I). 
Eighty-eight percent of patients had FVIIc levels below 5%. Of the 101 bleeds, 93 were fully 
evaluable and eight (three treated with recombinant activated factor VII [rFVIIa; NovoSeven
®
, 
Novo Nordisk A/S, Bagsvӕrd, Denmark], four with fresh frozen plasma [FFP; provided locally by 
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the blood transfusion services] and one with prothrombin complex concentrate [PCC; 
Prothromplex™ Baxter, Deerfield, IL, USA]) were evaluated for adverse events only. Of the 30 
haemarthroses, seven were reported as ‘traumatic’, as were 10 of the 16 muscle and subcutaneous 
haematomas, two of the 13 gum bleeds and one patient with easy bruising (Tables 2 and 3).  
Recombinant FVIIa was given to treat 79/101 episodes (room temperature stable rFVIIa in 
five [Tables 2 and 4]); plasma-derived FVII (pdFVII) concentrates (Provertin™ Baxter, Deerfield, 
USA or Facteur VII, LFB Lille, France) were used in seven, FFP in 12, and PCC in three bleeding 
episodes (Tables 3 and 4). Outcomes with rFVIIa were excellent in 38 and effective in 35 of the 79 
cases (partly effective in three and not evaluable in three). Plasma-derived FVII concentrates were 
associated with excellent outcomes in three, effective in three and partially effective in one of the 
seven cases. Of the eight evaluable cases treated with FFP, outcome was effective in seven cases 
and partially effective in one. PCC provided an excellent outcome in two cases (the third was not 
evaluable). RT data and outcomes are summarized in Table 4. Four cases of re-bleeding were 
reported, three of which were treated with rFVIIa (Table 2), and one with FFP (Table 3): in one 
case re-bleeding was traumatic (heel) as it occurred at another site, but did not require further 
treatment; in two cases re-bleeding occurred after one-day RT for epistaxis; the fourth case was 
treated with one-day FFP treatment for gum bleeding that relapsed after 24 hours. One patient 
received a prolonged RT for a haemorrhoidal bleeding, a problem that was surgically resolved. 
Concomitant administration of anti-fibrinolytic agents was reported in 10 patients (six with 
menorrhagia, three with epistaxis and one with haemorrhoidal bleeding).  Only one patient with 
menorrhagia was on the combined pill. 
No thrombotic episodes were reported during the 30-day follow-up. Two inhibitors were 
detected 30 days after RT (maximum titres: 2.1 and 22.4 BU).  
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Discussion 
Randomly occurring bleeding episodes, either ‘spontaneous’ or traumatic, represent the 
current treatment requirement for patients with a CBD. These ‘non-surgical’ bleeds may be sporadic 
or recurrent, depending on the severity of the disease and environmental events (13). In patients 
with haemophilia, the vast majority of all bleeding episodes occur in the joints and muscles (13, 
14), but in autosomally transmitted bleeding disorders, the clinical picture is more varied, 
comprising mild, muco-cutaneous bleeds, but also other limb- or life-threatening bleeds (1-4, 6, 7). 
All patients described in this study were previously symptomatic and some of them exhibited 
almost the entire array of bleeds described in FVII deficiency (7). These composite clinical pictures 
were confirmed by clotting phenotypes characterized by FVIIc levels <5% in 88% of the patients. 
Our study cohort is representative of the spectrum of symptoms observed in FVII deficiency, 
especially in its more severe manifestations.  
Haemarthroses in FVII deficiency display the same clinical features as in haemophilia, but 
the overall frequency (≈10%) of this crippling haemorrhage appears reduced in comparison to that 
observed in severe haemophilia (7). However, if only patients with residual FVIIc levels <2% are 
considered, the difference is reduced (14/40 [35%] in this study and 42/117 [35.9%] in the 
International Registry on Congenital Factor VII Deficiency (IRF7) cohort. A distinctive feature in 
FVII deficiency is that haemarthroses occur, for obvious genetic reasons, with comparable 
prevalence in males (20.7%) and females (18.6%) (7). Furthermore, those patients with recurrent 
joint bleeds were shown to have very low FVIIc levels (7), a feature that is confirmed in this 
analysis (Table 1). Regarding treatment, the schedules adopted were mostly based on a single-
day/single-dose treatment (15/27, 55%). On average, the dose of rFVIIa associated with excellent 
outcomes was intermediate (median 60 µg/kg), higher than expected, but one should consider that 
haemostasis was ensured with one bolus of a factor with a very short half-life. Ten equally effective 
treatments were performed with schedules based on multiple and higher dosages (median 120 
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µg/kg) (Table 4). Therefore, the overall favourable response rate of joint bleeds to rFVIIa treatment 
can be considered very satisfactory (92%). 
Haematomas (muscle or subcutaneous) can be as painful as haemarthroses and, if large 
enough, can cause compartment syndrome, muscle fibrosis and contractures. For the nine patients 
treated with rFVIIa, an efficacious one-day schedule (one to three doses) was used with a total dose 
equal to that used for joint bleeds (median ≈60 µg/kg) (Table 4); treatments with PCC (n=3) or FFP 
(n=12) appeared less effective but, given the small number of patients, firm conclusions cannot be 
drawn (Tables 3 and 4).  
Menorrhagia is highly prevalent in patients with CBD (60–100% of cases, depending on disease 
type and severity). This frequent bleeding symptom seriously impairs patients’ quality of life and 
can cause iron-deficient anaemia in the medium or long term (15). Menorrhagia is also highly 
prevalent in FVII-deficient patients (63% of the cases in the fertile age) (7), with a clear relationship 
with FVIIc levels: women with menorrhagia were shown to have significantly lower FVIIc levels 
than those without (4.5% vs. 14%, p<0.001) (7). Furthermore, girls with FVIIc <9% carry a five-
fold risk of developing menorrhagia in comparison to those with higher FVIIc levels (7). In the 
present study, RT with rFVIIa for menorrhagia provided satisfactory results: the outcome was 
excellent in six and effective in eight of the 14 cases. However, of note is that substitution does not 
aim to stop bleeding but to reduce it, and since quantitative evaluation of menstrual blood loss is not 
currently performed, it is not possible to determine the extent to which blood loss was reduced. RT 
duration varied from one-day (9/14 cases) to multiple-day administrations (two days: 2/14 cases; ≥3 
days: three cases), with no apparent difference in efficacy. As with haemarthroses, intermediate, 
total doses of 50 µg/kg were associated with efficacious outcomes (Table 4). From these data, it 
appears that schedules based on single or multiple administrations in the first day of the cycle are 
not inferior to multiple-day schedules, but this finding needs to be substantiated by larger studies 
and objective measurements.  
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Epistaxis and gum bleeding are very frequent symptoms of FVII deficiency (7) that are 
usually managed with local measures (tampons, anti-fibrinolytics), but may sometimes require RT. 
Considering the small number of reports on these bleeds available, we have evaluated these two 
mucosal bleeds together; rFVIIa was employed with excellent or effective outcomes (17/19 
patients), and pdFVII appeared equally effective (Tables 3 and 4). Other treatments for muco-
cutaneous bleeds have been reported (Tables 3 and 4), but numbers are too small to draw 
conclusions. 
Although the treatment of most of the episodes of CNS bleeds (8/9) was reported to be 
satisfactory (one excellent, six effective and one partially effective), due to the short RT duration, 
firm conclusions on outcomes cannot be drawn. As reported in previous studies (2, 6, 7, 16), these 
bleeding episodes occur mostly in unweaned or young babies and require intense RT schedules, i.e. 
short- or long-term prophylaxis courses; therefore, on-demand treatment does not appear to be the 
best choice.  
Overall, rFVIIa administrations yielded excellent (i.e. one-day/one dose) responses in 38/79 
(48%) and effective responses in 35 (44%) bleeds, with median dosages of 60 µg/kg (Table 4). The 
need for medium to high doses may be explained by the short half-life (mean half-life: 2.73 hours 
[11 individuals]) and the low in vivo recovery (a mean 0.59 [90 individuals]) for rFVIIa observed in 
a study in progress (17). Plasma-derived FVII concentrates may provide an alternative to rFVIIa, 
but little experience has been gained in this study and availability is becoming a problem (Table 4). 
As the number of patients treated with plasma or plasma-derived concentrates was limited, a 
formal comparison between rFVIIa and the other substitutions was not possible. It is evident that 
FFP, though used in children, was not associated with satisfactory results, but one has to consider 
that in some countries this is the only choice available. Concomitant anti-fibrinolytics were used in 
too few patients to allow an efficacy evaluation.  
No thrombotic episodes were reported to be associated with any type or RT dose in any of 
the patients, even prior to this study. Two inhibitors were detected, one after rFVIIa and the other 
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after pdFVII, in two repeatedly treated patients: including this study, three inhibitors have been 
detected so far. While the inhibitor prevalence in FVII deficiency appears to be in the range of that 
reported for haemophilia B, the lack of a definitive denominator in our still on going study does not 
allow any firm conclusions to be drawn. Of note, no anaphylactoid reactions were reported, 
notwithstanding the similar structure of the missing factor and the fact that all of the inhibitor 
patients continued to be treated after the inhibitor detection. 
To conclude, most bleeding episodes in patients with FVII deficiency can be successfully 
treated, with a good safety outcome, using a single-day, single-dose schedule of rFVIIa at 
‘intermediate’ doses. Although side effects are very rare, screening for inhibitors to FVII is 
recommended. 
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Table 1. Demographics and clinical and clotting phenotypes. 
 
Patient number Gender Age (y) FVIIc (%) Number of 
recorded 
symptoms 
Type of recorded symptoms 
1 Female 12 <1.0 4 Br; Hr; Hp; Me 
2 Male 3 <1.0 5 Br; Ep; Gu; Mu; Sc 
3 Female 6 <1.0 2 CNS; Gu 
4 Female 46 <1.0 3 Ep; Gu; Me 
5 Female 1 <1.0 2 CNS; Um 
6 Male 64 <1.0 5 Gi; Gu; Hr; Hm; Mu 
7 Female 22 <1.0 1 Me 
8 Male 13 <1.0 7 Br; Ep; Gi; Gu; Hr; Mu; Sc 
9 Female 20 <1.0 5 Br; Ep; Gu; Hm; Me 
10 Female 19 <1.0 5 Br; Ep; Gu; Hm; Me 
11 Female 23 <1.0 1 Me 
12 Male 59 <1.0 4 Br; Ep; Gi; Hr 
13 Female 7 <1.0 2 Hr; Mu 
14 Female 20 <1.0 2 Gi; Me 
15 Male 29 <1.0 1 Gi 
16 Female 5 <1.0 6 CNS; Br; Ep; Gi; Gu; Mu 
17 Female 54 <1.0 6 Br; Ep; Gum; Hp; Hb; Me 
18 Female 8 <1.0 2 Hr; Sc 
19 Female 4 days <1.0 4 Br; Gi; Sc; Um 
20 Female 11 1.0 6 Ep; Gu; Hr; Me; Mu; Sc 
21 Male 7 1.0 1 Hr 
22 Female 5 1.0 1 Hr 
23 Female 45 1.0 3 CNS; Br; Me 
24 Female 58 1.0 9 CNS; Br; Gu; Hr; Hm; Hb; Me; Mu; Sc 
25 Male 0.1 1.0 1 Gi 
26 Female 71 1.0 4 Br; Ep; Gu; Mu 
27 Female 48 1.0 2 Hr; Mu 
28 Female 17 1.0 3 Ep; Gu; Me 
29 Female 13 1.0 2 Ep; Gu 
30 Male 16 1.0 2 Ep; Gu 
31 Male 7 1.0 1 Ep 
32 Female 0.2 1.0 2 CNS; Gi; Hb 
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33 Male 0.6 1.1 1 CNS 
34 Female 21 1.3 6 Ep; Gum; Hr; Me; Mu; Sc 
35 Male 0.4 1.3 1 Gi; Gu 
36 Female 5 1.4 1 Br 
37 Female 0.5 1.5 3 CNS; Gu; Sc 
38 Female 14 1.6 1 Gu 
39 Female 7 1.7 9 Br; Ep; Gi; Gu; Hr; Hm; Mu; Sc; Um 
40 Male 7 1.7 7 Br; Ep; Gi; Hr; Hm; Mu; Sc 
41 Female 7 2.0 2 Br; Gu 
42 Male 1.1 2.0 3 Br; Mu; Sc 
43 Female 7 2.0 3 Br; Ep; Mu 
44 Male 12 2.0 2 Ep; Gu 
45 Male 18 2.0 2 Ep; Gu 
46 Female 1.5 2.1 2 Ep; Mu 
47 Male 12.5 2.2 5 Br; Ep; Gi; Gu; Hr 
48 Male 6 2.4 7 Br; Ep; Gu; Hr; Mu; Sc; Um 
49 Male 11 2.5 5 Ep; Gi; Gu; Hr; Mu 
50 Female 13 2.5 3 Br; Ep; Gu 
51 Female 13 2.5 1 Hr 
52 Male 1 2.5 6 CNS; Br; Ep; Gu; Mu; Sc 
53 Female 13 2.7 7 CNS; Br; Ep; Gu; Hr; Me; Sc 
54 Female 19 3.0 5 Br; Ep; Gu; Me; Mu 
55 Female 4 3.0 2 Mu; Sc 
56 Male 32 3.0 2 CNS; Hr 
57 Male 32 3.0 2 CNS; Hr 
58 Male 32 3.0 2 CNS; Hr 
59 Male 32 3.0 2 CNS; Hr 
60 Male 2 3.0 1 Br 
61 Male 10 3.0 1 Hr 
62 Male 8 3.0 1 Hr 
63 Female 11 3.0 6 Br; Ep; Gu; Hr; Mu; Sc 
64 Male 32 3.0 2 CNS; Hr 
65 Female 11 4.0 1 Hp 
66 Female 44 4.0 1 Me 
67 Female 25 5.0 6 Br; Ep; He; Me; Sc; Um 
68 Male 4 5.0 7 CNS; Br; Gi; Gu; Mu; Sc; Um 
69 Male 40 5.7 2 Ep; Hr 
70 Female 59 7.0 1 Mu 
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71 Male 17 9.0 1 Gu 
72 Male 3 9.0 1 Ep 
73 Male 2 17.0 1 Ep 
74 Male 4 20.0 1 Ep 
75 Male 46 20.0 1 Hb 
 
Br, bruising; CNS, central nervous system bleeding; Ep, epistaxis; FVIIc, FVII coagulant activity; Gi, gastrointestinal bleeding; Gu; gum; Hb, haemorrhoidal 
bleeding; He, haematuria; Hm, haemorrhoidal; Hp, haemoperitoneum; Hr, haemarthrosis; Me, menorrhagia; Mu, muscle; Sc, subcutaneous haematoma; Um, 
umbilical bleeding. 
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Table 2. rFVIIa schedules and outcome by bleeding type. 
 
Symptom and 
patient number  
(ref. Table 1) 
Trauma Replacement therapy schedule Anti-
fibrinolytics 
Outcome Adverse event 
 Days 
(n) 
Total 
number 
of doses 
Total 
dose 
(µg/kg) 
Mean dose 
(µg/kg) 
   
CNS bleeding         
23 No 1 8 160 20 No Partly effective No 
3 Yes 1 3 90 30 No Effective No 
32 No 14 87 2,610 30 No Effective No 
32 No 3 6 90 15 No Effective No 
19 No 2 8 240 30 No Excellent No 
35 No 1 3 90 30 No Effective No 
15 No 1 8 160 20 No Effective No 
47 No 1 8 200 25 No Effective No 
Haemarthrosis         
8 No 1 2 120 60 No Effective No 
18 Yes 1 3 240 80 No Effective No 
21 No 1 5 300 60 No Effective No 
22 No 1 7 210 30 No Effective No 
24 No 1 1 18 18 No Excellent No 
39 Yes 1 1 28 28 No Excellent No 
26 Yes 1 1 30 30 No Excellent No 
26 Yes 1 5 90 18 No Effective No 
56 No 2 2 120 60 No Effective No 
56 No 1 1 60 60 No Excellent No 
56 No 1 1 60 60 No Excellent No 
48 Yes 2 2 104 52 No Effective No 
69 No 1 1 30 30 No Partly effective No 
57 No 1 1 60 60 No Excellent No 
57 No 1 1 60 60 No Excellent No 
57 No 1 1 60 60 No Excellent No 
34 Yes 1 1 20 20 No Excellent No 
58 No 2 4 180 45 No Effective No 
58 No 1 1 60 60 No Excellent No 
58 No 1 1 60 60 No Excellent No 
59 No 1 1 60 60 No Excellent No 
59 No 1 2 120 60 No Effective No 
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59 No 1 1 60 60 No Excellent No 
63 No 1 1 35 35 No Excellent Rebleeding 
64 No 3 3 180 60 No Partly effective No 
42 No 1 4 100 25 No Effective No 
6 No 1 1 10 10 No Excellent No 
Haematomas 
(musc and subcut) 
        
27 No 1 1 26 26 No Excellent No 
70 No 1 2 26 13 No Effective No 
48 Yes 1 1 54 54 No Excellent No 
40 Yes 1 1 57 57 No Excellent No 
52 Yes 1 1 65 65 No Excellent Inhibitor 
2 Yes 1 1 80 80 No Excellent No 
13 Yes 1 3 75 25 No Effective No 
37 No 1 3 60 20 No Effective No 
42 Yes 1 4 100 25 No Effective No 
Menorrhagia         
20 No 3 4 50 12.5 Yes Excellent No 
20 No 2 4 50 12.5 Yes Excellent No 
7 No 1 1 20 20 No Effective No 
7 No 1 1 20 20 No Effective No 
7 No 1 1 270 270 No Effective No 
11 No 1 1 20 20 No Excellent No 
1 No 6 8 80 10 Yes Excellent No 
1 No 3 5 40 8 Yes Effective No 
14 No 2 8 240 30 No Effective No 
28 No 1 2 60 30 No Effective No 
4 No 1 2 90 45 No Effective No 
34 No 1 1 41 41 No Excellent No 
34 No 1 1 20 20 No Excellent No 
66 No 1 8 240 30 No Effective No 
Gum bleeding         
48 No 1 1 52 52 No Excellent No 
38 No 1 1 30 30 No Excellent No 
71 No 1 2 60 30 No Effective No 
44 No 1 1 30 30 No Excellent No 
29 Yes 1 1 30 30 No Excellent No 
30 No 1 2 60 30 No Effective No 
45 No 1 1 50 50 No Excellent No 
45 No 1 1 50 50 No Excellent No 
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Epistaxis         
42 No 1 2 50 25 No Effective No 
31 No 1 1 60 60 No Excellent Re-bleeding 
31 No 1 8 480 60 No Effective No 
16 No 1 2 40 20 No Effective No 
74 No 1 2 180 90 Yes Effective Re-bleeding 
73 No 1 1 90 90 Yes Excellent No 
53 No 1 1 26.6 26.6 No Excellent No 
43 No 1 1 66 66 No Excellent No 
72 No 1 1 160 160 No Excellent No 
72 No 1 1 142 142 No Not evaluable No 
45 No 1 1 50 50 No Not evaluable No 
Others         
Haemorr. bleed 75 No 12 75 3,600 48 Yes Not evaluable No 
Easy bruising 60 Yes 1 4 120 30 No Effective No 
 
CNS, central nervous system; Haemorr, haemorrhoidal; musc, muscle; rFVIIa, recombinant activated factor VII; subcut, subcutaneous. 
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Table 3. Plasma and plasma-derived concentrates use and outcome by bleeding type. 
 
Drug 
and 
patient 
number 
(ref. 
Table 1) 
Symptoms Trauma Replacement therapy schedule Anti-
fibrinolytics 
Outcome Adverse 
event 
  RT 
days 
(n) 
Total 
number 
of doses 
Total dose Mean 
dose 
   
FFP §           
33 CNS bleeding No 1 1 15 15 No Effective No 
68 GI bleeding No 1 1 33 33 No Not evaluable No 
41 Gum bleeding No 1 1 10  10 No Effective No 
50 Gum bleeding No 1 2 20  10 No 
Partly 
effective 
No 
50 Gum bleeding No 1 2 35 17.5 No Not evaluable 
Re-
bleeding 
51 Haemarthrosis No 1 2 20 10 No Not evaluable No 
61 Haemarthrosis No 1 1 10  10 No Effective No 
54 Haematomas * No 1 2 20  10 No Effective No 
46 Haematomas * No 6 12 120 10 No Not evaluable No 
55 Haematomas * No 1 2 20 10 No Effective No 
41 Menorrhagia No 1 1 10  10 Yes Effective No 
62 Haematoma * Yes 1 1 10  10 No Effective No 
PCC °          
49 Haemarthrosis Yes 1 1 38 38 No Excellent No 
39 Haematomas * Yes 1 1 30 30 No Excellent No 
26 Haematomas * Yes 1 1 30 30 No Not evaluable No 
pdFVII^          
74 Epistaxis No 1 2 56 28 Yes Effective No 
12 GI bleeding No 2 3 60 20 No Effective No 
17 Gum bleeding Yes 1 1 33 33 No Excellent Inhibitor 
10 Gum bleeding No 1 1 21 21 No Excellent No 
74 Haematomas * Yes 1 2 56 28 No Effective No 
67 Haematuria No 1 1 18 18 No Excellent No 
9 Menorrhagia No 3 4 133 33 Yes 
Partly 
Effective 
No 
 
CNS, central nervous system; FFP, fresh frozen plasma; GI, gastrointestinal; musc, muscle; PCC, prothrombin complex concentrate; pdFVII, plasma-derived FVII; RT, 
replacement therapy; subcut, subcutaneous. * Muscle and Subcutaneous; § ml/Kg; ° IU; ^ IU 
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Table 4. Summary of treatments.  
Treatment  N Days of 
treatment 
(median and 
range) 
Number of 
doses 
(median and 
range) 
Total dose Outcome 
Median Range Excellent  
(1 dose) 
Effective  
(>1 dose) 
Partially 
effective 
Ineffective Not  
evaluable 
rFVIIa 79 1 (1–14) 1 (1–87) 60 µg/kg 10–3600 38 35 3 – 3 
Haemarthrosis 27 1 (1–3) 1 (1–7) 60 µg/kg 10–300 15 10 2 – – 
Menorrhagia 14 1 (1–6) 2 (1–8) 50 µg/kg 20–270 6 8 – – – 
Epistaxis and gum bleeding 19 1 (1–1) 1 (1–8) 52 µg/kg 27–480 12 5 – – 2 
CNS  8 1 (1–14) 8 (3–87) 160 µg/kg 90–2610 1 6 1 – – 
Haematomas (muscle and 
subcutaneous) 
9 1 (1–1) 1 (1–3) 60 µg/kg 26–100 5 4 – – – 
Other 2 1 (1–12) 4 (4–75) 120 µg/kg  100–3600 – 2 – – 1 
FFP 12 1 (1–6) 1 (1–12) 15 ml/kg 10–120 – 7 1 – 4 
pdFVII 7 1 (1–3) 2 (1–4) 56 IU 21–133 3 3 1 – – 
PCC 3 1 (1–1) 1 (1–1) 30 IU 30–38 2 – – – 1 
 
CNS, central nervous system; FFP, fresh frozen plasma; PCC, prothrombin complex concentrate; pdFVII, plasma-derived FVII; rFVIIa, recombinant activated factor VII. 
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Additional table requested for Original Articles  
What is known about this topic? 
• Previously, patients with inherited factor VII deficiency were poorly characterised from a 
clinical standpoint, and only anecdotal evidence was available on schedules and dosages. 
• Reported treatments with rFVIIa were from retrospective collation of data. 
• Very little was known in terms of fresh frozen plasma use. 
• Single, anecdotal data only were available on the development of inhibitors to FVII. 
• No data were available on thrombosis occurrence. 
What does this paper add? 
• A clear cut definition of the clinical picture of FVII deficient patients and of bleeding 
episodes needing treatment. 
• Useful indications on schedules and dosages for rFVIIa, focussed on the most frequent 
bleeds. 
• Insights into the limitations and efficacy of FFP. 
• Preliminary data on the prevalence of inhibitor occurrence. 
• Preliminary, though meaningful, data on the rarity of thrombotic events in these patients. 
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